Michael Gelband’s Quince Therapeutics QNCX Stock Holding History

Michael Gelband’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-113	Closed	-$633K	–	2510
2020 Q4	$633K	Buy	+113	New	+$1M	0.01%	1104

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's QNCX Position: Q1 2022 in Review

Michael Gelband sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 153 shares — an estimated $385K sold.

Michael Gelband first reported a position in QNCX in Q4 2020 and held it in 4 quarters. The position peaked at $385K in Q4 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

Michael Gelband reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
Michael Gelband sold 153 Quince Therapeutics shares in Q1 2022, an estimated $385K.
Michael Gelband first reported a position in Quince Therapeutics in Q4 2020 and held it in 4 quarters.
Michael Gelband's Quince Therapeutics position peaked at $385K in Q4 2021.
85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.